Aptose Biosciences Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 17 - Subsequent Events (Details Textual)

Note 17 - Subsequent Events (Details Textual) - USD ($)						12 Months Ended
Note 17 - Subsequent Events (Details Textual) - USD ($)	Mar. 18, 2025	Feb. 12, 2025	Feb. 07, 2025	Jan. 30, 2024	Sep. 06, 2023	Dec. 31, 2024	Dec. 31, 2023	Mar. 14, 2025	Feb. 03, 2025	Dec. 31, 2022	Nov. 04, 2021
Positive shareholder's equity						$ (4,543,000)	$ (2,901,000)			$ 37,741,000
Nasdaq Listing Rule, minimum requirement for stockholders' equity						$ 2,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						13,606	7,232
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)						$ 59.97	$ 296.1
Future expense associated with option						$ 400,000
Common Stock, Shares Outstanding						2,006,028	264,745
Warrants outstanding						1,267,585
Common shares issued under the ESPP plan (Shares)						922	195
Public Offering [Member]
Common shares issued (in shares)				188,304
Proceeds from Issuance of Common Stock, Gross				$ 9,700,000
Warrants to purchase common shares, exchange price				$ 51.3
Private Placement [Member]
Proceeds from Issuance of Common Stock, Gross				$ 4,000,000
Over-Allotment Option [Member]
Shares Issued, Price Per Share				$ 51.3
Shares Issued, Price Per Share (in dollars per share)				$ 51.3
Common shares issued upon exercise of stock options				$ 24,561
Common Stock [Member]
Positive shareholder's equity						$ 457,404,000	$ 444,806,000			$ 437,520,000
Common shares issued under the ESPP plan (Shares)						922	195
Common Stock [Member] \| Public Offering [Member]
Warrants to purchase common shares, number of warrants				188,174
Hanmi Pharmaceuticals [Member]
Shares Issued, Price Per Share						$ 51.3
Issuance of common shares					$ 3,000,000
Shares Issued, Price Per Share (in dollars per share)						$ 51.3
Number of common shares held						99,647					7,190
Warrants to purchase common shares, number of warrants						77,972
Common Stock, Shares Outstanding						99,647	29,471
Hanmi Pharmaceuticals [Member] \| Public Offering [Member]
Premium share price (as a percent)				11.00%
Hanmi Pharmaceuticals [Member] \| Private Placement [Member]
Shares Issued, Price Per Share				$ 57
Common shares issued (in shares)				70,175
Shares Issued, Price Per Share (in dollars per share)				$ 57
Warrants to purchase common shares, exchange price				$ 51.3
Hanmi Pharmaceuticals [Member] \| Common Stock [Member] \| Private Placement [Member]
Warrants to purchase common shares, number of warrants				77,972		77,972	0
Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						12,939	5,621
Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						667	1,611
Share-Based Payment Arrangement, Tranche One [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%	50.00%
Share-Based Payment Arrangement, Tranche One [Member] \| Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						50.00%	50.00%
Share-Based Payment Arrangement, Tranche Two [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						16.67%	16.67%
Share-Based Payment Arrangement, Tranche Two [Member] \| Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						25.00%	25.00%
Share-Based Payment Arrangement, Tranche Three [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						16.67%	16.67%
Share-Based Payment Arrangement, Tranche Three [Member] \| Options with Three Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						25.00%	25.00%
Share-based Payment Arrangement, Tranche Four [Member] \| Options with Four Year Vesting [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage						16.67%	16.67%
Subsequent Event [Member]
Nasdaq Listing Rule, minimum requirement for stockholders' equity								$ 2,500,000
Common shares issued under the ESPP plan (Shares)			333
Subsequent Event [Member] \| Commitment Shares [Member]
Stock issuance program authorized shares			8,020
Subsequent Event [Member] \| Debt Conversion Agreement
Convertiable debt amount	$ 1,500,000
Common shares converted	409,063
Shares Issued, Price Per Share	$ 3.7
Shares Issued, Price Per Share (in dollars per share)	$ 3.7
Subsequent Event [Member] \| 2025 ATM Facility
Stock Issuance Program, Authorized Amount									$ 1,000,000
Stock Issuance, Percent of Cash Commission to Broker									3.00%
Shares Issued, Price Per Share		$ 7.31
Common shares issued (in shares)		137,000
Proceeds from Issuance of Common Stock, Gross		$ 999,000
Issuance of common shares		$ 961,000
Shares Issued, Price Per Share (in dollars per share)		$ 7.31
Subsequent Event [Member] \| Maximum [Member]
Stock Issuance Program, Authorized Amount			$ 25,000,000
Amount agreed to pay for reasonable expenses under purchase agreement			$ 25,000